Camp4 Therapeutics vs Xenon Pharmaceuticals
CAMP and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAMP and XENE compare
Xenon Pharmaceuticals is the larger company, worth 15 times as much as Camp4 Therapeutics ($4.0B against $257M).
Camp4 Therapeutics grew revenue faster over the last twelve months (39.9% versus −100% for Xenon Pharmaceuticals).
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 6 for Camp4 Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAMP | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $257M | $4.0B |
| Share price | $4.09 | $40.99 |
| Change, 1 year | −0.97% | 2.7% |
| Change, 5 years | −98.2% | 41.4% |
| Beta (5Y) | 2.72 | 0.62 |
| Employees | 48 | 370 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 48.2× | – |
| P/B | 2.4× (better) | 3.5× |
| FCF yield | −10.3% | −9.0% (better) |
| Fair value | $2.51 | – |
| Margin of safety | −63.0% | – |
| Growth | ||
| Revenue growth (TTM) | 39.9% (better) | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Operating margin | −1001% | – |
| Net margin | −2276% | – |
| FCF margin | −496% | – |
| Return on equity | −146% | −50.3% (better) |
| Return on invested capital | – | −251% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.42 | 21.19 (better) |
| Altman Z-score | 1.52 | 42.33 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 104% |
| Held by insiders | 21.7% | 0.17% |
| Insider net buying, 12 months | −$2.4M (better) | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.6% | 7.6% |
Go deeper
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.